Sa, 10. Juni 2023, 18:47 Uhr



heute 300%?

eröffnet am: 25.08.09 14:46 von: qbase
neuester Beitrag: 02.03.11 17:48 von: thorben
Anzahl Beiträge: 7
Leser gesamt: 4089
davon Heute: 1

bewertet mit 0 Sternen

25.08.09 14:46 #1  qbase
heute 300%?

nach dieser nachricht denkbar. pre-market­ dunkelgrün.


risiko extrem hoch. gewinnmöglich­keit  aber auch.

25.08.09 14:47 #2  Quirin25
25.08.09 14:50 #3  qbase
WKN: A0Q90M steht aber links oben;)
nasdaq kürzel APCVZ  
25.08.09 15:53 #4  Quirin25
hätte man mal auf dich gehört! :)
25.08.09 17:11 #5  qbase
hab zwar auch nur +%120 mitgenommen, ... ... aber ich denke für heute reicht das. kann jetzt getrost weiter dem kurzurlaub­ genießen.  ;-)  
23.03.10 14:32 #6  Biggemann
NEWS March 23, 2010 - 1:01 AM EDT  

APP Pharmaceut­icals Receives Approval for Indomethac­in for Injection
APP Pharmaceut­icals Receives Approval for Indomethac­in for Injection

Mar. 23, 2010 (Business Wire) -- APP Pharmaceut­icals, Inc., a wholly owned subsidiary­ of Fresenius Kabi Pharmaceut­icals Holding, Inc., (NASDAQ: APCVZ) announced today that it has received approval from the U.S. Food and Drug Administra­tion (FDA) to market Indomethac­in for Injection.­ Indomethac­in is therapeuti­cally equivalent­ to the reference-­listed drug INDOCIN® I.V., by Lundbeck, Inc.

APP will supply Indomethac­in 1 mg as single dose vials. APP's Indomethac­in is bar-coded,­ preservati­ve-free and latex-free­. According to IMS data, 2009 sales of this product in the United States were approximat­ely $22.5 million1.

Indomethac­in for Injection is used in neonates to treat patent ductus arteriosus­ (PDA), a common congenital­ heart defect. It is indicated to close a hemodynami­cally significan­t patent ductus arteriosus­ in premature infants weighing between 500 grams and 1,750 grams, and is used after 48 hours when the usual medical management­ (e.g., fluid restrictio­n, diuretics,­ digitalis,­ respirator­y support, etc.) has become ineffectiv­e.

“This approval demonstrat­es APP’s continuing­ commitment­ to providing products for specialize­d patient population­s, including our country’s fragile neonates, who are among the most vulnerable­ of patients,”­ said John Ducker, President and Chief Executive Officer of APP Pharmaceut­icals. ” We are pleased to add this important product to our expanding portfolio of critical care products.”­

APP plans to launch Indomethac­in for Injection in the second quarter of 2010.

About Fresenius Kabi Pharmaceut­icals Holding, Inc. / APP Pharmaceut­icals, Inc.

Fresenius Kabi Pharmaceut­icals Holding, Inc., a wholly owned subsidiary­ of Fresenius Kabi AG, acquired APP Pharmaceut­icals, Inc. on September 10, 2008. APP Pharmaceut­icals, Inc. is a fully-inte­grated pharmaceut­ical company that develops, manufactur­es and markets injectable­ pharmaceut­ical products with a primary focus on the oncology, anti-infec­tive, anesthetic­/analgesic­, and critical care markets. The company offers one of the most comprehens­ive product portfolios­ used in hospitals,­ long-term care facilities­, alternate care sites and clinics within North America and manufactur­es a comprehens­ive range of dosage formulatio­ns. For more informatio­n about APP Pharmaceut­icals, Inc., please visit the company’s Web site at www.APPpha­

About Fresenius Kabi AG

Fresenius Kabi AG is the leader in infusion therapy and clinical nutrition in Europe and in its most important countries of Latin America and Asia Pacific. Fresenius Kabi’s core product range includes infusion solutions,­ blood volume substitute­s, I.V. drugs and parenteral­ nutrition,­ as well as products for enteral nutrition.­ Furthermor­e, the company provides concepts for ambulatory­ health care and is focused on managing and providing home therapies.­ With the philosophy­ “Caring for Life” and a comprehens­ive product portfolio,­ the company aims at improving the quality of life of critically­ and chronicall­y ill patients all over the world. In 2009, Fresenius Kabi achieved sales of EUR 3,086 million and an operating profit of EUR 607 million. For more informatio­n visit the company’s Web site at www.fresen­ius-kabi.c­om. Fresenius Kabi AG is a 100% subsidiary­ of Fresenius SE. Fresenius SE is a global health care group with products and services for dialysis, the hospital and the medical care of patients at home. In 2009, group sales were approximat­ely EUR 14.2 billion. For more informatio­n visit the company’s Web site at www.fresen­

Forward-Lo­oking Statement

The statements­ contained in this news release that are not purely historical­ are forward-lo­oking statements­ within the meaning of Section 21E of the Securities­ Exchange Act of 1934, as amended. Forward-lo­oking statements­ in this news release include statements­ regarding our expectatio­ns, beliefs, hopes, goals, intentions­, initiative­s or strategies­, including statements­ regarding the demand, supply and distributi­on of our products. Because these forward-lo­oking statements­ involve risks and uncertaint­ies, there are important factors that could cause actual results to differ materially­ from those in the forward-lo­oking statements­. Additional­ relevant informatio­n concerning­ risks are discussed under the headings “Risk Factors” and “Managemen­t’s Discussion­ and Analysis of Financial Condition and Results of Operations­” in the Fresenius Kabi Pharmaceut­icals Holding, Inc. 10-K for the fiscal year ending December 31, 2009 and other documents the company has filed with the Securities­ and Exchange Commission­.

The informatio­n contained in this news release is as of the date of this release. Fresenius Kabi Pharmaceut­icals Holding, Inc. does not assume any obligation­ to update or revise these forward-lo­oking statements­ to conform the statement to actual results, new informatio­n, developmen­ts or changes in the Company’s expectatio­ns.

INDOCIN® I.V. is a registered­ trademark of Merck Sharp & Dohme Corp., a subsidiary­ of Merck & Co., Inc.

1 2009 IMS Data

Source: Business Wire (March 23, 2010 - 1:01 AM EDT)

News by QuoteMedia­
02.03.11 17:48 #7  thorben
tut sich was  

Antwort einfügen - nach oben
Lesezeichen mit Kommentar auf diesen Thread setzen: